MD, PhD J.A. Barranger, MS, CGC E.O. Rice, BS J. Dunigan, BS C. Sansieri, MD N. Takiyama, BS M. Beeler, BS J. Lancia, BS S. Lucot, BS S. Scheirer-Fochler, BS T. Mohney, BS W. Swaney, PhD A. Bahnson, MD E. Ball
{"title":"戈谢病:基因转移到造血细胞的研究","authors":"MD, PhD J.A. Barranger, MS, CGC E.O. Rice, BS J. Dunigan, BS C. Sansieri, MD N. Takiyama, BS M. Beeler, BS J. Lancia, BS S. Lucot, BS S. Scheirer-Fochler, BS T. Mohney, BS W. Swaney, PhD A. Bahnson, MD E. Ball","doi":"10.1016/S0950-3536(97)80039-X","DOIUrl":null,"url":null,"abstract":"<div><p>Transfer of the gene coding for glucocerebrosidase (GC) via a retroviral vector (MFG-GC) to haematopoietic progenitors results in engraftment and life-long expression of the human protein at high levels in transplanted mice. Studies of human CD34 cells were carried out to evaluate their potential use in a gene therapy approach to Gaucher's disease. High transduction efficiency and correction of the enzyme deficiency was possible in CD34 cells obtained from patients with Gaucher's disease. Based on these results, a clinical trial of gene therapy was designed and initiated. Preliminary results of this study indicate the persistence or engraftment of genetically corrected cells in the transplanted patients.</p></div>","PeriodicalId":77029,"journal":{"name":"Bailliere's clinical haematology","volume":"10 4","pages":"Pages 765-778"},"PeriodicalIF":0.0000,"publicationDate":"1997-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S0950-3536(97)80039-X","citationCount":"31","resultStr":"{\"title\":\"9 Gaucher's disease: studies of gene transfer to haematopoietic cells\",\"authors\":\"MD, PhD J.A. Barranger, MS, CGC E.O. Rice, BS J. Dunigan, BS C. Sansieri, MD N. Takiyama, BS M. Beeler, BS J. Lancia, BS S. Lucot, BS S. Scheirer-Fochler, BS T. Mohney, BS W. Swaney, PhD A. Bahnson, MD E. Ball\",\"doi\":\"10.1016/S0950-3536(97)80039-X\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Transfer of the gene coding for glucocerebrosidase (GC) via a retroviral vector (MFG-GC) to haematopoietic progenitors results in engraftment and life-long expression of the human protein at high levels in transplanted mice. Studies of human CD34 cells were carried out to evaluate their potential use in a gene therapy approach to Gaucher's disease. High transduction efficiency and correction of the enzyme deficiency was possible in CD34 cells obtained from patients with Gaucher's disease. Based on these results, a clinical trial of gene therapy was designed and initiated. Preliminary results of this study indicate the persistence or engraftment of genetically corrected cells in the transplanted patients.</p></div>\",\"PeriodicalId\":77029,\"journal\":{\"name\":\"Bailliere's clinical haematology\",\"volume\":\"10 4\",\"pages\":\"Pages 765-778\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1997-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/S0950-3536(97)80039-X\",\"citationCount\":\"31\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Bailliere's clinical haematology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S095035369780039X\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bailliere's clinical haematology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S095035369780039X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
9 Gaucher's disease: studies of gene transfer to haematopoietic cells
Transfer of the gene coding for glucocerebrosidase (GC) via a retroviral vector (MFG-GC) to haematopoietic progenitors results in engraftment and life-long expression of the human protein at high levels in transplanted mice. Studies of human CD34 cells were carried out to evaluate their potential use in a gene therapy approach to Gaucher's disease. High transduction efficiency and correction of the enzyme deficiency was possible in CD34 cells obtained from patients with Gaucher's disease. Based on these results, a clinical trial of gene therapy was designed and initiated. Preliminary results of this study indicate the persistence or engraftment of genetically corrected cells in the transplanted patients.